Answers are grounded in this paper and cite their sources.
Novel phage φKP-C01 shows efficacy against KL102 CRKP infections, indicating new therapeutic strategies.
Background: The emergence and spread of carbapenem-resistant Klebsiella pneumoniae (CRKP) represent a major threat to global public health, necessitating effective therapeutic strategies to prevent infection. Materials and Methods: A novel bacteriophage, φKP-C01, was isolated and characterized using ST307 KL102 CRKP as the host. Results: One-step growth curve analysis and complete genome sequencing demonstrated φKP-C01 to be a highly efficient lytic phage. The absence of genes encoding virulence factors, drug resistance determinants, or lysogeny-related functions indicated its potential safety for therapeutic applications. Bioinformatic analysis identified orf5 as encoding Depo-C01, a putative tail fiber protein with predicted depolymerase activity. To validate this function, orf5 was cloned, and recombinant Depo-C01 was expressed and purified. Depolymerase activity specifically targeting the KL102 capsular polysaccharide of the CRKP host was confirmed via spot assay and transmission electron microscopy. Conclusion: Lytic phage φKP-C01 and its depolymerase Depo-C01 show strong potential for phage-based or enzymatic strategies targeting CRKP infections.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: